Stocks Health care ALMS
NASDAQ · Health careAlumis Inc. (ALMS)
Alumis Inc. brought in $7.4M of revenue over the twelve months to June 30, 2026. It posted a net loss of $439M. In fiscal 2025 capital spending exceeded operating cash flow by $370.2M. At June 30, 2026 it held $63.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Alumis Inc.
- Net worth
- Alumis Inc. has a market value (market cap) of $828.4M at the latest share price, and shareholders' equity of $452.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $24.1M, with a net loss of $243.3M. Over the 12 months to June 30, 2026: revenue $7.4M, net loss $439M.
- Cash flow
- In fiscal 2025 operations used $369.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alumis Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Alumis Inc. does
Alumis Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALMS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $24.1M | -$243.3M | -$2.86 | -$370.2M |
| 2024 | n/a | -$294.2M | -$10.38 | -$256.8M |
| 2024 | n/a | -$155M | -$72.08 | -$134.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALMS ranks in Health care
Latest SEC filings
What Alumis Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- September 1, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 38% to $1.7M versus the same quarter last year; diluted EPS -$1.11 versus $0.77.
- August 13, 2026
- August 10, 2026Other event 8-K
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- July 2, 2026
- June 29, 2026Other event 8-K
Insider trades
What the people running Alumis Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $10.7M and sold $1M worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Hardiman Roy C.Chief Business & Strategy Ofcr | Sold | 652 | $4.3K |
| November 2, 2026 | Schroer John R.Chief Financial Officer | Sold | 794 | $5.2K |
| November 2, 2026 | Goldstein David MChief Scientific Officer | Sold | 629 | $4.1K |
| November 2, 2026 | Drappa JornChief Medical Officer | Sold | 593 | $3.9K |
| November 2, 2026 | Bradley Mark ChristopherChief Development Officer | Sold | 623 | $4.1K |
| November 2, 2026 | Pangali SanamChief Legal Officer | Sold | 332 | $2.2K |
| September 8, 2026 | Akkaraju SrinivasDirector | Soldindirect | 48,066 | $507K |
| September 8, 2026 | Akkaraju SrinivasDirector | Soldindirect | 48,065 | $507K |
Who owns ALMS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| James B. Tananbaum (“Tananbaum”)13D, may seek influence with 11 related filers | 29.2% | July 5, 2024 |
| James B. Tananbaum13D, may seek influence with 6 related filers | 14.5% | August 17, 2026 |
| AyurMaya Capital Management Company, LP13D, may seek influence with 1 related filers | 12.3% | July 2, 2026 |
| Samsara BioCapital, L.P.13D, may seek influence with 2 related filers | 6.9% | August 27, 2024 |
| Deep Track Capital, LP13G, passive with 2 related filers | 5.98% | April 7, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.5% | August 6, 2026 |
| Srinivas Akkaraju13D, may seek influence with 4 related filers | 5.4% | January 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 198 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| AyurMaya Capital Management Company, LP | 15,139,707 | 0 |
| BlackRock, Inc. | 8,218,151 | +1,047,283 |
| Fmr LLC | 6,769,170 | +5,795,388 |
| Deep Track Capital, LP | 6,348,558 | -424,037 |
| Samsara Biocapital, LLC | 6,345,219 | 0 |
| Foresite Capital Management V, LLC | 5,896,995 | 0 |
| venBio Partners LLC | 4,528,408 | 0 |
| Foresite Capital Management VI LLC | 4,247,670 | 0 |
| Vanguard Capital Management LLC | 4,215,703 | +183,437 |
| Nextech Invest Ltd. | 3,540,998 | 0 |
| Cormorant Asset Management, LP | 3,285,596 | -663,645 |
| Saturn V Capital Management LP | 2,915,443 | -286,632 |
| Octagon Capital Advisors LP | 2,830,700 | 0 |
| Jupiter Topco LLC | 2,355,122 | new |
| State Street Corp | 2,187,266 | +385,454 |
| Geode Capital Management, LLC | 2,168,517 | +250,102 |
| Mpm Bioimpact LLC | 2,019,020 | -367,509 |
| Baker Bros. Advisors LP | 2,012,500 | 0 |
| SR One Capital Management, LP | 1,959,896 | 0 |
| Invesco Ltd. | 1,173,518 | -338,019 |
Insiders
14 insiders reported holding 4,756,518 shares in total, about $30.4M at the last price.
| Holder | Shares |
|---|---|
| Akkaraju SrinivasDirector | 2,302,3362,298,783 held indirectly |
| Foresite Labs, LLC10% owner | 680,486680,486 held indirectly |
| Tananbaum James B.Director, 10% owner | 680,486680,486 held indirectly |
| Foresite Capital Management VI LLC10% owner | 680,486680,486 held indirectly |
| Hardiman Roy C.Chief Business & Strategy Ofcr | 207,094 |
| Drappa JornChief Medical Officer | 56,299 |
| Bradley Mark ChristopherChief Development Officer | 47,910 |
| Goldstein David MChief Scientific Officer | 30,341 |
| Yao ZhengbinDirector | 27,082 |
| Schroer John R.Chief Financial Officer | 23,924 |
Questions about ALMS
What does Alumis Inc. do?
Alumis Inc. is a company in the Health care sector, listed on NASDAQ as ALMS. Its shares trade on NASDAQ under the ticker ALMS.
What is Alumis Inc.'s net worth?
Alumis Inc. has a market value (market cap) of $828.4M at the latest share price, and shareholders' equity of $452.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alumis Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $439M on revenue of $7.4M.
How much revenue does Alumis Inc. make?
Over the twelve months to June 30, 2026 Alumis Inc. reported revenue of $7.4M.
When did Alumis Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Alumis Inc.'s next earnings report?
Alumis Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALMS with
Follow ALMS
Get an email when Alumis Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alumis Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.